Alphabet’s drug-design company has raised $7.7 billion across three announced rounds. The next milestone is not another financing. It is a first human trial.
Isomorphic Labs raised $5 billion in a Series C announced Nov. 17, giving Alphabet’s AI drug-design company more than twice…
Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue
October 8, 2026
Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…
